Slater, K.; Heeran, A.B.; Garcia-Mulero, S.; Kalirai, H.; Sanz-Pamplona, R.; Rahman, A.; Al-Attar, N.; Helmi, M.; O’Connell, F.; Bosch, R.;
et al. High Cysteinyl Leukotriene Receptor 1 Expression Correlates with Poor Survival of Uveal Melanoma Patients and Cognate Antagonist Drugs Modulate the Growth, Cancer Secretome, and Metabolism of Uveal Melanoma Cells. Cancers 2020, 12, 2950.
https://doi.org/10.3390/cancers12102950
AMA Style
Slater K, Heeran AB, Garcia-Mulero S, Kalirai H, Sanz-Pamplona R, Rahman A, Al-Attar N, Helmi M, O’Connell F, Bosch R,
et al. High Cysteinyl Leukotriene Receptor 1 Expression Correlates with Poor Survival of Uveal Melanoma Patients and Cognate Antagonist Drugs Modulate the Growth, Cancer Secretome, and Metabolism of Uveal Melanoma Cells. Cancers. 2020; 12(10):2950.
https://doi.org/10.3390/cancers12102950
Chicago/Turabian Style
Slater, Kayleigh, Aisling B. Heeran, Sandra Garcia-Mulero, Helen Kalirai, Rebeca Sanz-Pamplona, Arman Rahman, Nebras Al-Attar, Mays Helmi, Fiona O’Connell, Rosa Bosch,
and et al. 2020. "High Cysteinyl Leukotriene Receptor 1 Expression Correlates with Poor Survival of Uveal Melanoma Patients and Cognate Antagonist Drugs Modulate the Growth, Cancer Secretome, and Metabolism of Uveal Melanoma Cells" Cancers 12, no. 10: 2950.
https://doi.org/10.3390/cancers12102950
APA Style
Slater, K., Heeran, A. B., Garcia-Mulero, S., Kalirai, H., Sanz-Pamplona, R., Rahman, A., Al-Attar, N., Helmi, M., O’Connell, F., Bosch, R., Portela, A., Villanueva, A., Gallagher, W. M., Jensen, L. D., Piulats, J. M., Coupland, S. E., O’Sullivan, J., & Kennedy, B. N.
(2020). High Cysteinyl Leukotriene Receptor 1 Expression Correlates with Poor Survival of Uveal Melanoma Patients and Cognate Antagonist Drugs Modulate the Growth, Cancer Secretome, and Metabolism of Uveal Melanoma Cells. Cancers, 12(10), 2950.
https://doi.org/10.3390/cancers12102950
